Table 1.
Characteristics of new patients with cervical cancer presenting at gynecology and general surgery clinics for investigations and treatment over a course of six years before and during the COVID-19 pandemic.
| Variables * | Pre-Pandemic (n = 340) |
During Pandemic (n = 52) |
p-Value |
|---|---|---|---|
| Age, years (mean ± SD) | 38.6 ± 8.1 | 37.4 ± 8.6 | 0.324 |
| BMI, kg/m2 (mean ± SD) | 23.3 ± 4.4 | 23.8 ± 5.2 | 0.457 |
| Tumor size, n (%) | 0.248 | ||
| <2 cm | 133 (39.2%) | 16 (30.3%) | |
| ≥2 cm | 207 (60.8%) | 36 (69.2%) | |
| FIGO stage, n (%) | 0.047 | ||
| I | 135 (39.7%) | 11 (21.1%) | |
| II | 82 (24.1%) | 13 (25.0%) | |
| III | 76 (22.4%) | 18 (34.6%) | |
| IV | 47 (13.8%) | 10 (19.2%) | |
| Differentiation grade, n (%) | 0.942 | ||
| Grade 1 | 191 (56.2%) | 29 (55.7%) | |
| Grade 2 | 105 (30.9%) | 17 (32.7%) | |
| Grade 3 | 44 (12.9%) | 6 (11.6%) | |
| Histology | 0.755 | ||
| Squamous-cell | 268 (78.8%) | 40 (76.9%) | |
| Adenocarcinoma | 72 (21.2%) | 12 (23.1%) | |
| Outcomes | |||
| Change in treatment plan | 41 (12.1%) | 12 (23.1%) | 0.030 |
| Postponed surgery | 32 (9.4%) | 11 (21.2%) | 0.011 |
| Postponed radio-chemotherapy | 44 (12.9%) | 15 (28.8%) | 0.002 |
| ICU hospitalization | 23 (6.8%) | 6 (11.5%) | 0.220 |
| Mortality | 20 (5.9%) | 4 (7.7%) | 0.612 |
* Data reported as n(%) unless specified differently.